From barefoot doctors and herbal medicine to a system of hospitals and modern pharmaceuticals, China’s healthcare system has made great strides.
With annual sales growth estimated to exceed 20 per cent, many global drug companies regard China as a “must-win” market.
But problems from basic delivery of services across the vast country to rampant corruption, beset the sector. GlaxoSmithKline’s bribery charges brought international attention to the problems. Measured by availability, price and quality, China has a long way to go.
您已閱讀10%（530字），剩余90%（4587字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。